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plantation has become the best treatment option for many
patients with early non-resectable hepatocellular carcinoma
(HCC), with expected ﬁve-year patient survivals in excess of
70% [1]. Despite strict candidate selection, some 10–15% of
patients still develop a post-transplant recurrence. While the
liver transplant community is endeavouring to lower these ﬁg-
ures, reﬁning selection criteria and exploring (neo-)adjuvant can-
cer treatments, the treatment of the patients with recurrence has
received little systematic attention and is still in its infancy,
mainly due to the limited number of patients.
Contributions, such as the one of Sposito et al. [2], shed some
new light on the issue: the investigators show that the tenet that
recurrences always lead to rapid death is no longer true, as some
15% (5/35) of the patients remain free of cancer after resection of
the recurrence. These ﬁndings provide evidence in favour of dili-
gent post-transplant protocols to detect recurrences early and
allow suggesting a management algorithm (Fig. 1).
From a theoretical point of view, patients can experience two
types of recurrences. Early recurrences may be the linked to
remaining (previously un-detected) extrahepatic HCC left at the
time of transplantation, or result from the post-transplant
engraftment of aggressive circulating HCC clones. Conversely,
late recurrences are linked to the engraftment of more indolent
and potentially less numerous circulating HCC cells [3]. These
two types of recurrences have differing expected outcomes, with
better survivals for patients with late recurrences [4]. These
expected outcomes should be kept in mind when offering a treat-
ment, as more side-effects can be accepted when decent chances
of cure or at least of prolonged survival can be foreseen. As an
example, some early intrahepatic HCC recurrences may be better
‘‘tested’’ by a locoregional treatment, prior to performing a resec-
tion, pending that no further disease appeared in the mean time.Journal of Hepatology 20
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Abbreviations: HCC, hepatocellular carcinoma; mTOR, mammalian target-of-
rapamycin.At the time of a diagnosis of recurrence, a decision should be
made whether to change the immunosuppression. Calcineurin
inhibitors have been associated with an increased risk of post-
transplant HCC recurrence [5], while mammalian target-of-rapa-
mycin (mTOR) inhibitors are considered as protecting from de
novo cancers and HCC recurrence [6]. Based on these (limited)
data, many groups, including ours, switch patients to mTOR
inhibitors at the time of recurrence (between 2007 and 2011,
seven patients managed by Sposito et al. were or had been put
on mTOR inhibitors at the time of recurrence). Overall, it appears
sensible to keep the immunosuppression as low as possible in
order to spare the anti-cancer immune activity.
Resection is the best treatment for both hepatic and extra-
hepatic single and oligonodular HCC recurrences [7], and this
option should always be explored ﬁrst. Unlike habitual HCCs,
most post-OLT HCC recurrences develop in non-cirrhotic livers
without portal hypertension, thus qualifying most patients for
surgery. In the report by Sposito et al., 57% (25/44) of patients
underwent a resection, and four were alive and free of HCC at a
median of 35.6 months after recurrence [2]. Other investigators
described improved outcomes after resection of lung HCC recur-
rences [8]. Of note, small (<3 cm) oligonodular hepatic recur-
rences can also be managed by radio-frequency ablation.
Sorafenib is a multi-tyrosine kinase and angiogenesis inhibi-
tor. It is a treatment option for patients with HCC recurrences
not amenable to surgery or locoregional treatment (n = 9), or in
case of progression after ﬁrst-line local (most often surgical)
treatment (n = 35), and the contribution of Sposito et al. provides
new data regarding the use of this drug for these speciﬁc
indications.
Fortunately, patients with post-transplant recurrences are
rare, imposing one of the limitations of the study, namely the
inclusion of ‘‘only’’ 39 patients over 17 years. In addition, patients
on sorafenib (n = 15) were different from controls (n = 24), as
they presented more factors previously associated with better
survival than patients on best supportive care. Sorafenib patients
were managed in the most recent years (2007–2011), when the
investigators were likely better in selecting good transplant can-
didates and more aggressive in the treatment of recurrence, and
sorafenib patients were more often on mTOR inhibitors and had13 vol. 59 j 3–5 Open access under CC BY-NC-ND license.
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Fig. 1. Proposed management of patients with post-transplant HCC recurrence. mTOR, mammalian target-of-rapamycin; RFA, radiofrequency ablation; TACE,
transarterial chemo-embolization; TARE, transarterial radio-embolization. ⁄Treatment invasiveness should be modulated according to the expected outcome: late
recurrences have better potential outcomes and may warrant more aggressive approaches. ⁄⁄Alone or combined to hepatic HCC recurrence.
Editoriallonger intervals between transplant and recurrence (38.1 vs.
15.7 months). Taking this into account, the uni-institutional
design was a strength, considering the consistent policies in
place, and the study’s main achievement was to provide an
updated and transparent summary on the state-of-the-art man-
agement of recurrence, whether the improved survival was
linked solely to sorafenib or not. The non-covariate-adjusted
median survival from the time of recurrence nearly doubled in
the sorafenib group compared to patients with best supportive
care (21.3 vs. 11.8 months, p = 0.0009). While this effect was
likely ampliﬁed by the previously mentioned variables, its signif-
icance remained after correction for covariates.
The synergistic effect of sorafenib and mTOR inhibitors
remains to be explored further, but Sposito et al. showed a trend
towards a better tumour response according to modiﬁed RECIST
criteria with the use of the combination (p = 0.0699). This obser-
vation is in line with previous reports [9–11], and further sup-
ports the revision of the immunosuppression protocol at the
time of HCC recurrence, favouring mTOR inhibitors. Of note, the
combined use of sorafenib and sirolimus does not lead to a
drug-drug interaction, and starting one drug should not require
any dose adjustment of the other [12].
The post-transplant side-effect proﬁle of sorafenib (especially
in combination to mTOR inhibitors) is a point of concern [13–18].
The reported adverse events included hand-foot skin reaction
(60%), diarrhea (40%) and fatigue (17%). They led to a dose reduc-
tion to 400 mg/day in more than half of the patients (target dose:
800 mg/day), only half of them recovering and being able to con-4 Journal of Hepatology 2tinue treatment at full dose. In addition, sorafenib was with-
drawn in a patient with renal and hepatic insufﬁciency. It is
difﬁcult to predict the occurrence of these effects, but one would
expect more adverse events in more fragile patients, especially
early after transplantation. Yet the management of recurrence
did not appear to be as gloomy as we thought in the past, and
overall, patients in the sorafenib group accumulated almost
5 years of survival from the time of transplantation (38.1 month
until recurrence and 21.3 months after recurrence).
A further advantage of the study is to draw attention to the
lengthening interval between transplantation and detection of
recurrence: in more recent years, the median time to recurrence
increased from 15.7 months to 38.1 months. Studies exploring
the safe expansion of selection criteria should take this into
account, increasing the length of follow-up necessary for mean-
ingful statistics.
Finally, the study by Sposito et al. also demonstrated that
61.7% of the recurring recipients had more advanced HCCs
(beyond Milan) on the explant pathology than expected from
the pre-transplant radiology [2]. This observation should promote
a careful pathological review of the explants, and potentially the
use of adjuvant post-transplant treatment in patients with signs
of HCC aggressiveness (i.e., microvascular invasion, poorly differ-
entiated HCC). Based on recent preliminary animal and clinical
data, sorafenib may also have an interest in this setting, but this
point remains to be conﬁrmed by more studies [19,20].
Managing post-transplant HCC recurrence is a challenging
ﬁeld due to the low incidence of the disease, and a prospective013 vol. 59 j 3–5
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randomized (or even a case-control matched) study would be
difﬁcult to design. Only multi-centric efforts would be possible,
but they would, by nature, bring more heterogeneity between
cases. The contribution of Sposito et al. represents one important
step towards the design of guidelines for the management of
these patients, and suggests that sorafenib has a reasonable ben-
eﬁt/side-effect balance in patients with non-resectable
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